Aydin O.,Kanarya D.,Yilmaz U.,Ü C.,Tunç C. .2022 .Determination of optimum ratio of cationic polymers and small interfering RNA with agarose gel retardation assay. Methods Mol. Biol, 2434 : 7-128.
Ahmadpour S.T.,Desquiret-Dumas V.,Yikilmaz U.,Dartier J.,Wetterwald C.,Orre C.,Gueguen N.,Brisson L.,Mahéo K.,Dumas J.F. .2021 .Doxorubicin-induced autophagolysosome formation is partly prevented by mitochondrial ROS elimination in DOX-resistant breast cancer cells. Int. J. Mol. Sci, 9283(17) : .
Barenholz Y. .2012 .--the first FDA-approved nano-drug: lessons learned. J. Control Release, 160(2) : 117-134.
.2012 .. , 03 : .
Banerjee K.,Kerzel T.,Bekkhus T.,Wallmann T.,Wallerius M.,Landwehr L.S.,Agardy D.A.,Schauer N.,Malmerfeldt A.,Bergh J.,Bartish M.,Hartman J.,Östman A.,Squadrito M.L.,Rolny C. .2023 .VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells. Cell Rep, 42(12) : 113507.
.2023 .. , 113507 : .
Cao Z.,Li Y.,Luo X.,Hua Z.,Wang X.,Xue Z.,Zhang Z.,Lu C.,Lu A.,Liu Y. .2023 .MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer. Breast Cancer Res., 25(1) : .
Charbe N.B.,Amnerkar N.D.,Ramesh B.,M.M. Tambuwala H.A.,Bakshi A.A.A.,Aljabali S.C.,Khadse R.,Satheeshkumar S.,Satija M.,Metha D.K.,Chellappan P.,Negi K.,Dua F.C,Zacconi F.C .2020 .Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta. Pharm. Sin. B., 10(11) : 2075-2109.
Dekkers J.F.,Whittle J.R.,Vaillant F.,Chen H.R.,Dawson C.,Geurts M.H.,Herold M.J.,Clevers H.,Lindeman G.J.,Visvader J.E. .2020 .Modeling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids. J. Natl. Cancer Inst., 112(5) : 540-544.
. .. , : .
Guo Q.F.,Sun J.Q. .2022 .Therapeutic effect of anti-miRNA mediated by RNA nanoparticles targeting CD133 on triple-negative breast cancer. Sci. Adv, 4269(4) : 803-809.
Hamanishi J.,Takeshima N.,Katsumata N.,Ushijima K.,Kimura T.,Takeuchi S.,Matsumoto K.,Ito K.,Mandai M.,Nakai H.,Sakuragi N.,Watari H.,Takahashi N.,Kato H.,Hasegawa K.,Yonemori K.,Mizuno M.,Takehara K.,Niikura H.,Sawasaki T.,Nakao S.,Saito T.,Enomoto T.,Nagase S.,Suzuki N.,Matsumoto T.,Kondo E.,Sonoda K.,Aihara S.,Aoki Y.,Okamoto A.,Takano H.,Kobayashi H.,Kato H.,Terai Y.,Takazawa A.,Takahashi Y.,Namba Y.,Aoki D.,Fujiwara K.,Sugiyama T.,I. Konishi T. .2021 .Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol., 39(33) : 3671-3681.
Harahap W.A.,Tofrizal T.,Oktahermoniza O. .2022 .Relationship between the expression of BRAF V600E and Ki-67 with the recurrence of well-differentiated thyroid cancer. Asian Pac. J. Cancer Prev, 23(11) : 3617-3622.
Iwamoto T.,Kajiwara Y.,Zhu Y.,Iha S. .2020 .Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. Chin Clin Oncol, 01(3) : .
Jin M.,Hou Y.,Quan X.,Chen L.,Gao Z.,Huang W. .2021 .Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties (II): co-delivery of Paclitaxel and VEGF siRNA for synergistic breast cancer therapy in mice. Int. J. Nanomedicine, 16 : 5479-5494.
Jin M.,Zeng B.,Liu Y.,Jin L.,Hou Y.,Wu H.,Chen L.,Gao Z.,W. Huang. Z. .2022 .Co-delivery of repurposing Itraconazole and VEGF siRNA by composite nanoparticulate system for collaborative anti-angiogenesis and anti-tumor efficacy against breast cancer. Pharmaceutics, 14(7) : .
Jamialahmadi K.,Zahedipour F.,G. Karimi. F. .2021 .The role of microRNAs on doxorubicin drug resistance in breast cancer. J Pharm Pharmacol, 73(8) : 997-1006.
Kopeckova K.,Eckschlager T.,Sirc J.,Hobzova R.,Plch J.,Hrabeta J.,J. Michalek. J. .2019 .Nanodrugs used in cancer therapy. Biomed. Pap. Med, 010(2) : 122-131.
Korpela H.,Hätinen O.P.,Nieminen T.,Mallick R.,Toivanen P.,Airaksinen J.,Valli K.,Hakulinen M.,Poutiainen P.,Nurro J.,Ylä-Herttuala S. .2021 .Adenoviral VEGF-B186R127S gene transfer induces angiogenesis and improves perfusion in ischemic heart. , 24(12) : 103533.
.2021 .. , 103533 : .
Karaosmanoglu S.,Zhou M.,Shi B.,Zhang X.,Williams G.R.,X. Chen. G.R. .2020 .Carrier-free nanodrugs for safe and effective cancer treatment. J. Control Release, 10 : 805-832.
Li C.,Wang H.,Fang H.,He C.,Pei Y.,Gai X. .2021 .FOXP3 facilitates the invasion and metastasis of non-small cell lung cancer cells through regulating VEGF, EMT and the Notch1/Hes1 pathway. Exp. Ther. Med, 22(3) : .
Lin Y.W.,Huang S.T.,Wu J.C.,Chu T.H.,Huang S.C.,Lee C.C.,M.H. Tai. C.C. .2019 .Novel HDGF/HIF-1α/VEGF axis in oral cancer impacts disease prognosis. BMC Cancer, 19(1) : 1083.
. .. , : .
Luchini C.,Pantanowitz L.,Adsay V.,Asa S.L.,Antonini P.,Veronese N.,Nottegar A.,Cingarlini S.,Landoni L.,Brosens L.A.,Verschuur A.V.,Mattiolo P.,Pea A.,Mafficini A.,Milella M.,Niazi M.K.,Gurcan M.N.,Eccher A.,Cree I.A.,Scarpa A .2022 .Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. Mod. Pathol., 35(6) : 712-720.
LoPresti M. L.,Arral N.,Chaudhary K.A.,Whitehead K.A. .2022 .The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J Control Release, 03 : 819-831.
Mercurio A.M. .2019 .VEGF/Neuropilin Signaling in Cancer Stem Cells. Int. J. Mol. Sci, 20(3) : 490.
Maryam S.S.,Ahmed R.,Alam M.U.,Hanif M.,Saleem R.,Gul R. .2021 .Role of serum VEGF-A biomarker for early diagnosis of ovarian cancer instead of CA-125. Pakistan Med, 71(9) : 688-2197.
Mainini F.,Eccles M.R. .2020 .Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules, 25(11) : 2692.
. .. , : .
Mi X.,Hu M.,Dong M.,Yang Z.,Zhan X.,Chang X.,Lu J.,Chen X. .2021 .Folic acid decorated zeolitic imidazolate framework (ZIF-8) loaded with Baicalin as a nano-drug delivery system for breast cancer therapy. Int. J. Nanomedicine, 16 : 8337-8352.
. .. , : .
Peng Y.,Wang Y.,Tang N.,Sun D.,Lan Y.,Yu Z.,Zhao X.,Feng L.,Zhang B.,Jin L.,Yu F.,Ma X.,Lv X. .2018 .Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J. Exp. Clin. Cancer Res., 37(1) : .
Repp L.,Rasoulianboroujeni M.,Lee H.J.,Kwon G.S.,PCL G.S. .2020 .-assemblies for injection. J. Control Release, 11 : 1004-1015.
Ramasamy T.,Ruttala H.B.,Munusamy S.,Chakraborty N.,Kim J.O. .2022 .Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J. Control Release, 352 : 861-878.
.2022 .. , 10 : .
Swietach P. .2019 .What is pH regulation, and why do cancer cells need it? Cancer Metastasis Rev. , 38(1-2) : 5-15.
Solechan S.,Suprihanto A.,Widyanto S.A.,Triyono J.,Fitriyana D.F.,Siregar J.P.,Cionita T. .2023 .Characterization of PLA/PCL/Nano-Hydroxyapatite (nHA) biocomposites prepared via cold isostatic pressing. Polymers (Basel), 15(3) : .
Vitale I.,Manic G.,Coussens L.M.,Kroemer G.,L. Galluzzi. G. .2019 .Macrophages and metabolism in the tumor microenvironment. Cell Metab, 06(1) : 36-50.
Wang A.,J.S. Jiang. A. .2022 .Research on mechanism of doxorubicin carried with mesoporous silica nanoparticles mesoporous silica nanoparticles in regulating the activity of liver tumor cells through regulating the activity of Hippo-Yes-Associated protein signal pathway. Sci. Adv, 4231(3) : 521-527.
Wu J. .2021 .The Enhanced Permeability and Retention (EPR) effect: the significance of the concept and methods to enhance its application. J. Pers. Med, 11(8) : .
Zhu X.,Chen L.,Huang B.,Wang Y.,Ji L.,Wu J.,Yu K.,Shao Z.,Z. Wang. Z. .2020 .The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci. Rep, 10(1) : 225.
. .. , : .
Zhang X.,Wu Z.,Peng Y.,Li D.,Jiang Y.,Pan F.,Li Y.,Lai Y.,Cui Z.,K. Zhang. Z. .2021 .Correlationship between Ki67, VEGF, and p53 and hepatocellular carcinoma recurrence in liver transplant patients. Biomed. Res. Int., 6651397 : .